AIM ImmunoTech completes first dosing for final patient in Phase 2 DURIPANC pancreatic cancer trial

AIM ImmunoTech Inc. Common Stock

AIM ImmunoTech Inc. Common Stock

AIM

0.00
  • AIM ImmunoTech dosed the final patient in its Phase 2 DURIPANC trial testing Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer.
  • Topline primary-endpoint results are expected in Q1 2027; secondary endpoint analyses are set to start in June 2027.
  • The study is designed to show whether the combination can deliver meaningful disease control in patients with advanced pancreatic cancer.
  • Management flagged exploratory biomarker work as a potential basis for selecting high-response patients in a future Phase 3 program.
  • No new efficacy results were presented in the announcement; the next data readouts are scheduled for late 2026 and early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180901PRIMZONEFULLFEED9748780) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.